Correlation and Predictors of EORTC QLQ-C30 GHS-QoL and EQ-5D VAS in Patients With Advanced NSCLC
Author(s)
Cindy Y. Kang, PhD Candidate. MSc. BPharm.1, Hui-Min Hsieh, PhD.1, Min-Hsi Lin, MD2, Ching-Yao Wang, MD2;
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Presentation Documents
OBJECTIVES: This study, conducted at a single center in Taiwan in 2024, collected patient-reported outcomes (PROs) using the EORTC QLQ-C30 and EQ-5D questionnaires from patients with advanced non-small cell lung cancer receiving PD-(L)1 inhibitors and/or chemotherapy. The study aims to examine the correlation between the EORTC QLQ-C30 Global Health Status/Quality of Life (GHS-QoL) and the EQ-5D Visual Analog Scale (VAS), and to identify potential predictors of GHS-QoL and VAS.
METHODS: This study employs a cross-sectional design within a longitudinal survey cohort. All first-time PRO measures from eligible patients were extracted. GHS and QoL were linearly transformed. Pearson’s correlation coefficients were calculated between GHS-QoL and VAS. Linear regression was used to predict GHS-QoL and VAS based on clinical factors.
RESULTS: This study included 126 patients; 42.9% female; mean and median age of 65 years (SD=9, IQR=59-71); and 18.3% receiving PD-(L)1 inhibitors. The mean GHS-QoL score was 54.23, and the mean VAS score was 67.55. The overall correlation between VAS and GHS-QoL was 0.62; correlations between GHS-VAS and QoL-VAS were 0.65 and 0.55, respectively. Scatterplots with linear fit lines are presented. The correlation between VAS and GHS-QoL was weaker in females (r=0.54) than males (r=0.69), potentially due to differences in educational attainment. Better ECOG performance status (PS; 0-1 vs. ≥2) and absence of bone metastasis were associated with stronger VAS-GHS-QoL correlations. PS was a significant predictor of GHS-QoL and VAS (worse PS, ≥2, associated with lower GHS-QoL and VAS). Other significant predictors of higher VAS scores included positive ICI exposure, college/university degree, and first-line treatment.
CONCLUSIONS: Correlations between GHS-QoL and VAS, both overall and after stratification, ranged from 0.4 to 0.8, indicating moderate to strong associations. Worse ECOG PS was associated with lower GHS-QoL and VAS scores. Use of PD-(L)1 inhibitors, college/university degree, and previously untreated status were associated with higher VAS scores.
METHODS: This study employs a cross-sectional design within a longitudinal survey cohort. All first-time PRO measures from eligible patients were extracted. GHS and QoL were linearly transformed. Pearson’s correlation coefficients were calculated between GHS-QoL and VAS. Linear regression was used to predict GHS-QoL and VAS based on clinical factors.
RESULTS: This study included 126 patients; 42.9% female; mean and median age of 65 years (SD=9, IQR=59-71); and 18.3% receiving PD-(L)1 inhibitors. The mean GHS-QoL score was 54.23, and the mean VAS score was 67.55. The overall correlation between VAS and GHS-QoL was 0.62; correlations between GHS-VAS and QoL-VAS were 0.65 and 0.55, respectively. Scatterplots with linear fit lines are presented. The correlation between VAS and GHS-QoL was weaker in females (r=0.54) than males (r=0.69), potentially due to differences in educational attainment. Better ECOG performance status (PS; 0-1 vs. ≥2) and absence of bone metastasis were associated with stronger VAS-GHS-QoL correlations. PS was a significant predictor of GHS-QoL and VAS (worse PS, ≥2, associated with lower GHS-QoL and VAS). Other significant predictors of higher VAS scores included positive ICI exposure, college/university degree, and first-line treatment.
CONCLUSIONS: Correlations between GHS-QoL and VAS, both overall and after stratification, ranged from 0.4 to 0.8, indicating moderate to strong associations. Worse ECOG PS was associated with lower GHS-QoL and VAS scores. Use of PD-(L)1 inhibitors, college/university degree, and previously untreated status were associated with higher VAS scores.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR214
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Oncology, STA: Personalized & Precision Medicine